Oxagen Limited is a privately-held biopharmaceutical company working in collaboration with Eleventa LLC to develop and commercialise OC000459 for the Russian and CIS markets.

OC000459 is a once-daily oral CRTH2 antagonist which has demonstrated encouraging activity in the treatment of eosinophilic asthma and allergic rhinoconjunctivitis, and an excellent safety profile.

www.oxagen.co.uk